Geraldine Pignot

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/135403/publications.pdf

Version: 2024-02-01

25 papers	750 citations	759233 12 h-index	642732 23 g-index
27 all docs	27 docs citations	27 times ranked	1514 citing authors

#	Article	IF	Citations
1	Survival Analysis of 130 Patients with Papillary Renal Cell Carcinoma: Prognostic Utility of Type 1 and Type 2 Subclassification. Urology, 2007, 69, 230-235.	1.0	211
2	microRNA expression profile in a large series of bladder tumors: Identification of a 3â€miRNA signature associated with aggressiveness of muscleâ€invasive bladder cancer. International Journal of Cancer, 2013, 132, 2479-2491.	5.1	152
3	Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer. OncoImmunology, 2019, 8, e1581556.	4.6	68
4	Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge?. European Urology, 2020, 77, 761-763.	1.9	51
5	Large-scale Real-time Reverse Transcription-PCR Approach of Angiogenic Pathways in Human Transitional Cell Carcinoma of the Bladder: Identification of VEGFA as a Major Independent Prognostic Marker. European Urology, 2009, 56, 678-689.	1.9	45
6	Systemic treatments for high-risk localized prostate cancer. Nature Reviews Urology, 2018, 15, 498-510.	3.8	36
7	Influence of previous or synchronous bladder cancer on oncologic outcomes after radical nephroureterectomy for upper urinary tract urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 23.e1-23.e8.	1.6	31
8	Correlation between messenger RNA expression and protein expression of immune checkpointâ€“associated molecules in bladder urothelial carcinoma: A retrospective study. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 257-263.	1.6	29
9	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. European Urology Oncology, 2019, 2, 355-364.	5.4	25
10	Oncological Outcomes of Delayed Nephrectomy After Optimal Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma. European Urology Oncology, 2022, 5, 577-584.	5.4	19
11	mRNA Expression levels of genes involved in antitumor immunity: Identification of a 3-gene signature associated with prognosis of muscle-invasive bladder cancer. OncoImmunology, 2017, 6, e1358330.	4.6	15
12	Loco-regional treatment for castration-resistant prostate cancer: Is there any rationale? A critical review from the AFU-GETUG. Critical Reviews in Oncology/Hematology, 2018, 122, 144-149.	4.4	13
13	PLEKHS1: A new molecular marker predicting risk of progression of nonâ€‘muscleâ€‘invasive bladder cancer. Oncology Letters, 2019, 18, 3471-3480.	1.8	10
14	Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer. Scientific Reports, 2020, 10, 16641.	3.3	10
15	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. World Journal of Urology, 2023, 41, 619-625.	2.2	8
16	â€œReal-worldâ€•evaluation of 18F-Choline PET/CT practices in prostate cancer patients and impact on changes in therapeutic strategy. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 2.e1-2.e9.	1.6	7
17	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. Clinical Genitourinary Cancer, 2022, 20, e339-e345.	1.9	6
18	Impact of sarcopenia status of muscle-invasive bladder cancer patients on kidney function after neoadjuvant chemotherapy. Minerva Urology and Nephrology, 2021, 73, 215-224.	2.5	4

#	Article	IF	Citations
19	Reply to Nirmish Singla and Vitaly Margulisa€™s Letter to the Editor re: Geraldine Pignot, Antoine Thiery-Vuillemin, Jochen Walz, et al. Nephrectomy After Complete Response to Immune Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma: A New Surgical Challenge? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.12.018. The Next Surgical Frontier in Kidney Cancer: Nephrectomy After Immune Checkpoint Inhibition. European Urology, 2020, 78, e81-e82.	1.9	2
20	Identifying the relevant population for neoadjuvant chemo-hormonal therapy combined with radical prostatectomy. Gland Surgery, 2020, 9, 495-497.	1.1	1
21	Enfortumab vedotin for cisplatin-ineligible urothelial cancer. Lancet Oncology, The, 2021, 22, 748-749.	10.7	1
22	Re: Pathologic Response and Surgical Outcomes in Patients Undergoing Nephrectomy Following Receipt of Immune Checkpoint Inhibitors for Renal Cell Carcinoma. European Urology, 2020, 78, 288.	1.9	1
23	Editorial Comment to Different methods of hilar clamping during partial nephrectomy: Impact on renal function. International Journal of Urology, 2014, 21, 237-237.	1.0	0
24	Self-reported functional assessment after treatment for prostate cancer: 5-year results of the prospective cohort VICAN. Future Oncology, 2022, , .	2.4	0
25	Surgical management in metastatic renal cell carcinoma. Bulletin Du Cancer, 2022, 109, 2S59-2S65.	1.6	0